Короткий опис (реферат):
Actuality. The product policy of manufacturers of medicines used for obstructive respiratory diseases is based on studying the pharmaceutical market of Ukraine, conducting an analysis of the assortment of medicines with the aim of updating it, ensuring profitability, and searching for new effective medicines. The aim of the study is to investigate the range of bronchodilators used in the treatment of obstructive respiratory diseases and to analyze their availability within the framework of the “Affordable Medicines” program. Material and methods. The objects of the study were the State Formulary of Medicines (sixteenth edition), the directory of medicines Compendium online, the Regulatory and directive documents of the Ministry of health of Ukraine, the State register of medicines of Ukraine, online resources – Apteki.ua. and Tabletki.ua. Marketing, graphical, logical generalization, and mathematical-statistical methods were used in the study.Research results. As of early 2025, 37 trade names of bronchodilators used for the treatment of obstructive respiratory diseases were registered in Ukraine. Among the studied medicines, imported produced drugs predominate, accounting for 59,46%. Germany ranks first among the importing countries in terms of the nomenclature of the studied medicines (22,73%) supplied to the domestic pharmaceutical market. The leading domestic manufacturers of bronchodilators are PJSC “Farmak” (20%) and LLC “Multispray” (20%). Among the studied medicines, 83,78% of the assortment consists of monocomponent medicines, while the rest are two-component medicines. Among the dosage forms of bronchodilators used for the treatment of obstructive respiratory diseases on the domestic pharmaceutical market, aerosol for inhalation predominate, accounting for 26,32%. These include both imported (6 trade names) and domestically produced (4 trade names) medicines. Currently, only four bronchodilators used for the treatment of obstructive respiratory diseases are included in the “Affordable Medicines” program: Salbutamol, Salbutamol-Neo, Spiriva®, and EasyFree®.Conclusion. The domestic pharmaceutical market of bronchodilators used in the treatment of obstructive respiratory diseases was studied. The results of the analysis support the feasibility of developing and introducing domestically produced bronchodilators into the pharmaceutical market of Ukraine.
